Corvus Pharmaceuticals (Corvus Pharmaceuticals) Effective Interest Rate on Debt % : 0.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Corvus Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.00 Mil. Corvus Pharmaceuticals's average total debt for the quarter that ended in Mar. 2024 was $1.21 Mil. Therefore, Corvus Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 0.00%.

Corvus Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Corvus Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Effective Interest Rate on Debt % Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

0.50

Corvus Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Corvus Pharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Corvus Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corvus Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Effective Interest Rate on Debt % falls into.

Corvus Pharmaceuticals Effective Interest Rate on Debt % Calculation

Corvus Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * 0	/	( (2.601	+	1.374)	/ 2 )
=	-1 * 0	/	1.9875
=	0.00 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.373	+	1.228
=	2.601

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	1.374
=	1.374

Corvus Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2023 )	+	Total Debt (Q: Mar. 2024 ))	/ count )
=	-1 * 0	/	( (1.374	+	1.04)	/ 2 )
=	-1 * 0	/	1.207
=	0.00 %

where

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	1.374
=	1.374

	Total Debt (Q: Mar. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	1.04
=	1.04

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Corvus Pharmaceuticals (NAS:CRVS) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Corvus Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

C17:Germany

Address

863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Executives

Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
William Benton Jones	officer: See Remarks	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Leiv Lea	officer: Chief Financial Officer	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Miller Richard A Md	director, officer: President and CEO	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell	director	1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher	officer: Chief Medical Officer	863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould	director, 10 percent owner	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy	officer: EVP Discovery Research	CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt	officer: SVP, Chief Business Officer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner	officer: V.P., Chemistry Research	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010